NCT04887792View on ClinicalTrials.gov

Acetazolamide for Treatment Resistant Schizophrenia

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 1, 2022

Primary Completion Date

June 30, 2026

Study Completion Date

December 30, 2026

Conditions
SchizophreniaSchizo Affective Disorder
Interventions
DRUG

Acetazolamide

ACZ 250 mg/day in gelatin capsules will be administered initially and increased over 7-10 days to 2g/day.

DRUG

Placebo

Identical gelatin capsules will be prepared by filling with inert excipients.

Trial Locations (2)

15213

RECRUITING

University of Pittsburgh, Pittsburgh

Unknown

RECRUITING

St John's Medical College Hospital, Bangalore

All Listed Sponsors
collaborator

Stanley Medical Research Institute

OTHER

lead

Vishwajit Nimgaonkar, MD PhD

OTHER